Bayer and PCF launch darolutamide challenge awards for prostate cancer
The two projects will be awarded $1m each to support their clinical investigations
Read More
Tag: Nubeqa
SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
Bayer’s Nubeqa wins NICE prostate cancer backing
Drug authorised for use in non-metastatic castration-resistant prostate cancer
Read More
Nubeqa success in Phase III prostate cancer study
“A positive trend in overall survival” had been seen in a trial, with an interim analysis demonstrating a 29% reduction in the risk of death for Nubeqa.
Read More
Nubeqa bags FDA green light
The drug has been approved under the governing body’s Priority Review designation.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
